List of Excipients in Branded Drug DIFLUPREDNATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	DIFLUPREDNATE OPHTHALMIC	difluprednate ophthalmic	0781-6000	BORIC ACID
Sandoz Inc	DIFLUPREDNATE OPHTHALMIC	difluprednate ophthalmic	0781-6000	CASTOR OIL
Sandoz Inc	DIFLUPREDNATE OPHTHALMIC	difluprednate ophthalmic	0781-6000	EDETATE DISODIUM

Generic Drugs Containing DIFLUPREDNATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	difluprednate	0378-7518	BORIC ACID
Mylan Pharmaceuticals Inc	difluprednate	0378-7518	CASTOR OIL
Mylan Pharmaceuticals Inc	difluprednate	0378-7518	EDETATE DISODIUM

What are the Most Frequently-Used Excipients in DIFLUPREDNATE?

# Of NDCs	Excipient
9	BORIC ACID
9	CASTOR OIL
9	EDETATE DISODIUM

Difluprednate Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Difluprednate is a high-value ophthalmic formulation opportunity because the active ingredient is delivered as a sterile oil-in-water emulsion rather than a simple aqueous solution. The commercial opportunity is concentrated in generic and differentiated ophthalmic emulsions, preservative-free delivery, multidose packaging, manufacturing platforms, and excipient systems that improve physical stability and patient tolerability.

Durezol, the reference product, contains difluprednate 0.05% and uses castor oil, polysorbate 80, glycerin, boric acid, sodium hydroxide, and purified water. The formulation requires control of emulsion droplet size, pH, viscosity, redispersibility, sterility, and container performance.[1]

What is difluprednate and how is it formulated?

Difluprednate is a topical ophthalmic corticosteroid used for inflammation and pain associated with ocular surgery and for endogenous anterior uveitis. The active ingredient is a fluorinated corticosteroid ester with very low aqueous solubility, making an emulsion dosage form commercially relevant.[1]

What excipients are used in Durezol?

Excipient	Primary formulation role	Commercial significance
Castor oil	Oil phase and solvent vehicle for difluprednate	Critical to drug loading and emulsion structure
Polysorbate 80	Nonionic surfactant and emulsifier	Controls oil-water interface and physical stability
Glycerin	Tonicity and humectant agent	Supports ocular tolerability and osmolality
Boric acid	Buffering and tonicity contribution	Helps maintain target pH and product stability
Sodium hydroxide	pH adjustment	Controls chemical stability and ocular comfort
Purified water	Continuous aqueous phase	Must meet sterile ophthalmic manufacturing standards

Durezol is a sterile ophthalmic emulsion with a target pH reported in the range of approximately 7.2 to 7.6.[1] The reference formulation does not rely on benzalkonium chloride as a listed inactive ingredient, which creates a commercial opening for preservative-free positioning and ocular-surface tolerability claims.

Why does difluprednate require an emulsion rather than an aqueous solution?

Difluprednate has limited water solubility. An oil-in-water emulsion allows the drug to be incorporated into an oil phase while maintaining a drop-compatible aqueous product. The formulation approach can improve dose uniformity, enable practical drug concentration, and avoid aggressive cosolvent systems that may irritate the ocular surface.

The key technical problem is not simply solubilizing difluprednate. Developers must maintain:

• Uniform drug distribution throughout the bottle
• Stable droplet size during shelf life
• Rapid redispersion after storage
• Controlled viscosity and drop size
• Chemical stability against hydrolysis and oxidation
• Sterility through the labeled in-use period
• Compatibility with the bottle, tip, cap, and seal
• Acceptable ocular comfort after administration

A formulation that matches assay but fails on redispersibility, droplet growth, creaming, or dose uniformity is unlikely to provide a robust generic or lifecycle-management product.

What excipient strategy is most attractive for difluprednate?

The strongest strategy is a controlled, low-complexity emulsion platform using established ophthalmic excipients. The commercial objective should be to preserve the pharmacologic and physical performance of the reference product while creating manufacturing or patient-use advantages.

Castor oil as the primary oil phase

Castor oil is a logical starting point because it is present in the reference product and can solubilize lipophilic corticosteroid esters. Supplier selection should focus on:

• Low peroxide and acid values
• Consistent fatty-acid composition
• Low bioburden and endotoxin
• Ophthalmic-grade documentation
• Lot-to-lot viscosity consistency
• Extractables and leachables profile
• Global regulatory acceptability

Alternative oils may create differentiation, but they increase formulation and regulatory risk. Candidate alternatives could include medium-chain triglycerides, refined mineral oils, or other pharmaceutically accepted lipids. Each change can affect drug partitioning, droplet size, ocular residence time, and bioequivalence.

Polysorbate 80 and surfactant optimization

Polysorbate 80 is a conventional ophthalmic emulsifier. It supports interfacial stabilization but can present oxidation and degradation concerns. A supplier or formulation developer may create value through:

• Low-peroxide polysorbate 80 grades
• Tighter control of free fatty acids
• Reduced surfactant concentration
• Mixed-surfactant systems
• Alternative nonionic surfactants
• Improved sterilization and storage controls

Surfactant substitution is commercially attractive but technically sensitive. A new surfactant can alter droplet size, interfacial film strength, drug release, ocular irritation, and the product’s comparative performance.

Glycerin, boric acid, and pH control

Glycerin contributes to tonicity and may improve comfort. Boric acid and sodium hydroxide provide pH adjustment and buffering capacity. These ingredients are inexpensive and widely available, so they provide limited standalone differentiation. Their value is in the total formulation design.

A generic developer should avoid unnecessary changes to these components unless the change supports a measurable benefit, such as:

• Improved pH stability
• Lower precipitation risk
• Better comfort
• Reduced viscosity drift
• Greater compatibility with unit-dose packaging
• Better stability after repeated bottle opening

What formulations are protected or differentiated in difluprednate products?

The reference product’s commercial formulation is differentiated by its sterile ophthalmic emulsion architecture rather than by a novel excipient class. Potential formulation IP areas include:

1. Difluprednate concentration and particle or droplet characteristics.
2. Specific oil-to-water ratios.
3. Surfactant combinations and concentration ranges.
4. pH and osmolality windows.
5. Emulsion manufacturing sequence.
6. Homogenization conditions.
7. Sterilization strategy.
8. Container-closure interaction.
9. Redispersibility and dose-uniformity performance.
10. Preservative-free multidose delivery.

A formulation patent is commercially meaningful only if the claimed parameters are difficult to design around and can be detected through product testing or manufacturing evidence. Broad claims covering known ophthalmic emulsion excipients may face validity and obviousness pressure. Narrow claims tied to defined droplet-size distributions, stability profiles, or manufacturing conditions may provide stronger practical protection.

When does difluprednate lose exclusivity?

Durezol received FDA approval in 2008 under NDA 022212.[1] Difluprednate is a small-molecule drug, so future generic entry proceeds through the abbreviated new drug application, or ANDA, pathway rather than the biosimilar pathway.

The relevant exclusivity and entry barriers are:

Barrier	Relevance to difluprednate
New chemical entity exclusivity	Likely expired based on the 2008 approval date
Pediatric exclusivity	Must be checked against FDA approval and labeling records
Listed patents	May delay or condition ANDA approval
Paragraph IV certification	Can trigger patent litigation
Formulation similarity	Important for ophthalmic-emulsion development
Clinical endpoint	Generic applicants generally rely on pharmaceutical equivalence and bioequivalence requirements
Manufacturing controls	Sterility and emulsion control can delay approval or launch

The exact commercial entry date depends on FDA Orange Book listings, any 30-month litigation stay, settlement terms, approval timing, and whether an ANDA applicant receives first-filer status.[2] Patent expiration should be assessed from the current Orange Book record rather than from the brand approval date alone.

What is the Orange Book status of difluprednate?

FDA’s Orange Book is the controlling source for listed patents, exclusivity codes, therapeutic equivalence evaluations, and approved product information.[2] Difluprednate’s Orange Book analysis should address:

• NDA 022212 and the reference listed drug
• Listed patents and expiration dates
• Use codes for postoperative inflammation and uveitis
• Any pediatric exclusivity period
• Approved generic strengths and dosage forms
• Therapeutic-equivalence ratings
• Patent certifications submitted by ANDA applicants

A Paragraph IV challenge would be commercially important because an ANDA applicant could seek approval before the listed patent expiry. The risk is highest where the challenger can demonstrate that the reference emulsion’s formulation claims are invalid, not infringed, or irrelevant to the proposed product.

Which companies are challenging difluprednate exclusivity?

The public record should be reviewed through FDA approval databases, the Orange Book, USPTO records, and federal court dockets to identify current ANDA applicants, patent certifications, and litigation. Difluprednate has a generic-product opportunity because the active ingredient is a small molecule and the dosage form is an established ophthalmic emulsion.

The principal competitive groups are:

• Established generic ophthalmic manufacturers
• Contract development and manufacturing organizations with sterile emulsion capability
• Specialty ophthalmology companies
• Branded companies pursuing preservative-free or device-enabled reformulations
• Excipient and packaging suppliers seeking formulation-platform partnerships

The commercial advantage will favor companies that already operate sterile ophthalmic filling lines and can demonstrate emulsion uniformity at commercial scale.

What patent litigation affects difluprednate?

Patent litigation risk is concentrated in three areas:

Composition and formulation patents

These may cover the oil phase, surfactant system, pH, concentration, droplet size, or stability profile. They can create a launch delay if the generic applicant files a Paragraph IV certification.

Method-of-use patents

Potential claims may address postoperative ocular inflammation, pain, or anterior uveitis. Method-of-use patents can be managed through a section viii statement or labeling strategy if the relevant use can be carved out of the generic label.[3]

Manufacturing and device patents

Sterile emulsion processing, bottle design, drop-control systems, and preservative-free multidose technology can create secondary barriers. These rights may not block an ANDA if the generic applicant uses a different process or container.

Settlement agreements, if any, should be analyzed for:

• Authorized generic provisions
• Launch dates
• Patent-license scope
• Royalty obligations
• Product-specific restrictions
• Restrictions on formulation or device changes
• Allocation of pediatric or uveitis indications

What generic entry risks exist for difluprednate?

Generic difluprednate presents moderate technical risk and potentially high execution risk. The active ingredient is established, but ophthalmic emulsions require more development work than simple solutions or suspensions.

Risk	Assessment	Commercial effect
API solubility	High	Limits formulation options
Emulsion stability	High	Can cause failed shelf-life or in-use studies
Sterile processing	High	Requires specialized manufacturing
Bioequivalence	Moderate to high	Product performance must align with the reference
Container compatibility	Moderate	Can affect dose delivery and impurities
Excipient availability	Low to moderate	Most excipients are commercially available
Pricing pressure	High	Generic ophthalmic markets typically compress rapidly
Differentiation	Moderate	Preservative-free and device strategies can protect margin

A generic launch may occur in several scenarios:

1. A conventional emulsion closely matching the reference product.
2. A preservative-free single-dose product.
3. A preservative-free multidose product using a specialized closure system.
4. A lower-cost product using a different but regulatorily acceptable oil-surfactant platform.
5. A branded reformulation with improved ocular-surface tolerability or dosing convenience.

How can excipient suppliers create commercial opportunities?

The largest opportunities are not in commodity glycerin or boric acid. They are in validated excipient systems and technical services that reduce development risk.

Low-peroxide surfactant supply

Polysorbate 80 with documented oxidative control can support longer shelf life and reduce impurity formation. Suppliers can differentiate through tighter specifications, packaging under controlled conditions, and ophthalmic-grade regulatory support.

Ophthalmic-grade castor oil

A supplier offering consistent, low-impurity castor oil with strong global documentation can become embedded in a generic formulation. Qualification barriers create recurring revenue after approval.

Ready-to-use emulsion platforms

Excipient manufacturers and CDMOs can offer premixed oil-phase systems or standardized emulsion concentrates. The advantage is reduced formulation screening and faster scale-up. The platform must remain flexible enough to support ANDA development without creating avoidable patent exposure.

Preservative-free multidose systems

Packaging is a major opportunity. A validated multidose bottle with microbial ingress protection can eliminate the need for a conventional preservative while preserving commercial convenience. The device must demonstrate:

• Microbial challenge performance
• Consistent delivered volume
• Low residual volume
• Compatibility with the emulsion
• Extractables and leachables control
• Usability for postoperative patients

Unit-dose packaging

Unit-dose vials can support preservative-free positioning and reduce in-use contamination risk. The tradeoff is higher packaging cost, more waste, and lower convenience compared with a multidose bottle.

How does difluprednate compare with competing ophthalmic corticosteroids?

Product	Active ingredient	Dosage form	Excipient and commercial profile
Durezol	Difluprednate 0.05%	Ophthalmic emulsion	High formulation complexity; strong opportunity for emulsion and device differentiation
Pred Forte	Prednisolone acetate 1%	Ophthalmic suspension	Suspension technology; shake-dependent dosing and particle control
Lotemax	Loteprednol etabonate	Suspension or gel	Differentiation through ester chemistry, gel systems, and ocular tolerability
Maxidex	Dexamethasone	Solution or suspension	Generally simpler formulation options depending on strength and dosage form
Fluorometholone products	Fluorometholone	Suspension or ointment	Lower-cost competition and established generic supply

Difluprednate may support premium pricing because its emulsion can provide a more consistent delivery profile than a conventional suspension. That advantage is commercially useful only if the formulation preserves comfort, stability, and dosing uniformity while avoiding excessive manufacturing cost.

What is the FDA regulatory status of difluprednate?

FDA approved Durezol for ophthalmic use in 2008.[1] Generic development is regulated through the ANDA pathway, subject to FDA requirements for pharmaceutical equivalence, product quality, sterility, container closure, and bioequivalence.[2,4]

The regulatory development package should include:

• API identity, purity, and impurity control
• Excipient qualification
• Droplet-size and particle-size characterization
• pH, osmolality, viscosity, and surface-tension data
• Assay and content uniformity
• In-vitro release or comparative performance data
• Sterility and preservative effectiveness where applicable
• Extractables and leachables
• Shipping and temperature-excursion studies
• In-use stability after repeated dosing
• Container-closure integrity

Changing the excipient system can shift the product from a straightforward generic strategy toward a more complex regulatory pathway. A materially different formulation may require additional clinical or comparative-performance evidence.

What geographic markets offer the best opportunities?

The United States offers the clearest value for an ANDA or specialty generic because of the FDA’s established pathway and the commercial value of ophthalmic products. Europe, Canada, Japan, and selected emerging markets provide follow-on opportunities, but excipient and device requirements differ.

Key geographic considerations include:

• FDA acceptance of the proposed inactive-ingredient profile
• European pharmacopoeia and excipient compliance
• Local requirements for preservative-free multidose systems
• Sterile manufacturing capacity
• Patent enforcement and settlement exposure
• Reference-product availability for comparative testing
• Public procurement and tender pricing
• Reimbursement for postoperative and uveitis indications

A global formulation should use excipients with broad pharmacopeial acceptance and avoid materials that require region-specific justification.

How strong is the difluprednate formulation opportunity?

The formulation opportunity is stronger than the commodity-excipient opportunity. Castor oil, glycerin, boric acid, and polysorbate 80 are readily sourced. The defensible value lies in the validated combination of excipients, process parameters, sterile manufacturing, and packaging.

The most attractive commercial targets are:

1. A low-cost generic emulsion with reliable redispersibility.
2. A preservative-free multidose product.
3. A single-dose product for ocular-surface-sensitive patients.
4. A CDMO platform for sterile corticosteroid emulsions.
5. A low-peroxide excipient package supported by regulatory documentation.
6. A branded lifecycle product with device or tolerability differentiation.

Public product-level revenue for Durezol and difluprednate is not consistently disclosed by current commercial rights holders. Revenue exposure should therefore be modeled from prescription volume, reimbursement, generic entry timing, tender pricing, and the share of postoperative versus uveitis use rather than from a single reported brand figure.

Key Takeaways

• Difluprednate is best developed as a sterile ophthalmic emulsion because of its low aqueous solubility.
• The reference formulation uses castor oil, polysorbate 80, glycerin, boric acid, sodium hydroxide, and purified water.
• The highest-value excipient opportunities involve low-peroxide polysorbate 80, ophthalmic-grade castor oil, and validated emulsion systems.
• Preservative-free multidose packaging is the strongest product-differentiation opportunity.
• Generic entry uses the ANDA pathway, not the biosimilar pathway.
• Patent risk should focus on formulation, method-of-use, manufacturing, and container patents listed in the current Orange Book and related court records.
• The main technical barriers are emulsion stability, sterility, dose uniformity, redispersibility, and container compatibility.
• Commercial returns will depend heavily on launch timing, generic competition, manufacturing scale, and reimbursement.

FAQs

Can difluprednate be formulated as an ophthalmic solution?

Difluprednate’s low aqueous solubility makes a conventional solution difficult. An emulsion, suspension, or specialized solubilized system is more commercially practical.

Is benzalkonium chloride required in difluprednate eye drops?

No. The listed Durezol inactive ingredients do not include benzalkonium chloride.[1] This supports preservative-free formulation and packaging strategies.

Which excipient has the greatest impact on difluprednate performance?

Castor oil and polysorbate 80 have the greatest direct effect because they determine drug partitioning, droplet formation, emulsion stability, and dose uniformity.

Is a preservative-free difluprednate product commercially feasible?

Yes, but feasibility depends on sterile manufacturing, single-dose packaging, or a multidose container that prevents microbial ingress. The device can be as important as the excipient system.

Does difluprednate face biosimilar competition?

No. Difluprednate is a small-molecule drug. Competitors use the ANDA generic pathway rather than the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2008). Durezol (difluprednate ophthalmic emulsion) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2013). Approved drug products with therapeutic equivalence evaluations, 33rd edition.
4. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin.